# Johnson & Johnson data in psoriatic arthritis (PsA) shows TREMFYA (guselkumab) is the only advanced therapy to demonstrate MRI-confirmed improvements in spinal pain and stiffness

- Source: PR Newswire M&A
- Published: 2026-11-20T13:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/johnson--johnson-data-in-psoriatic-arthritis-psa-shows-tremfya-guselkumab-is-the-only-advanced-therapy-to-demonstrate-mri-confirmed-improvements-in-spinal-pain-and-stiffness-302946249.html
- Canonical: https://groundlevelnews.com/story/johnson-johnson-data-in-psoriatic-arthritis-psa-shows-tremfya-guselkum-270f42/

TREMFYA showed statistically significant improvement in disease activity on the BASDAI score versus placebo, reflecting meaningful reductions in pain, stiffness, swelling and fatigue in a Phase 4 study TREMFYA demonstrated more than 2 times greater reduction in MRI-assessed inflammation...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._
